1. Home
  2. ODTX

as of 11-20-2026 3:59pm EST

$16.85
$1.47
-8.02%
Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.

Founded: 2021 Country:
United States
United States
Employees: N/A City: BOSTON
Market Cap: 1.3B IPO Year: 2025
Target Price: $34.67 AVG Volume (30 days): 291.0K
Analyst Decision: Strong Buy Number of Analysts: 8
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -5.12 EPS Growth: N/A
52 Week Low/High: $15.10 - $29.05 Next Earning Date: 11-04-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): -100% Revenue Growth (next year): N/A
P/E Ratio: -3.58 Index:
Free Cash Flow: N/A FCF Growth: N/A

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K

Nov 4, 2026

0001193125-26-446174

EX-99.1

2 odtx-ex99_1.htm

EX-99.1

EX-99.1

Odyssey Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Additional analyses from the Phase 2a induction period for OD-001 further strengthen clinical proof of concept in ulcerative colitis

Completed IND-enabling studies for OD-002, a first-in-class oral SLC15A4 inhibitor

$387 million in cash, cash equivalents and marketable securities as of September 30, 2026, expected to fund operations into the second half of 2028

BOSTON, November 4, 2026 (GLOBE NEWSWIRE) - Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today reported financial results for the third quarter ended September 30, 2026, and provided an update on recent progress and anticipated milestones.

“Over the past several months, we have made meaningful progress across our entire pipeline, highlighted by additional analyses from the Phase 2a induction period for OD-001 demonstrating that clinical efficacy is supported by concordant biomarker and transcriptomic findings, further reinforcing previously established clinical proof of concept in patients with ulcerative colitis,” said Gary D. Glick, Ph.D., founder and chief executive officer of Odyssey Therapeutics. “We have also continued to advance the clinical development of OD-001 while completing IND-enabling studies for OD-002, our SLC15A4 inhibitor. Together with an enhanced executive leadership team and strong financial foundation, these achievements position us to execute on our clinical development strategy and drive continued progress throughout our portfolio.”

Recent Business Highlights and Developments

Pipeline developments

• OD-001: RIPK2 scaffolding inhibitor

o Presented additional Phase 2a induction results that strengthen clinical proof of concept. In October, Odyssey presented additional findings from the Phase 2a induction period involving 56 efficacy-evaluable patients with moderate-to-severe ulcerative colitis at United European Gastroenterology (UEG) Week and shared new clinical and translational analyses during a

company webcast. Clinical efficacy results are supported by concordant findings across clinical outcomes and inflammatory biomarkers, mucosal transcriptomics, and histologic improvement, further reinforcing the clinical proof of concept and providing additional biological evidence consistent with RIPK2 scaffolding inhibition.

• OD-002: SLC15A4 inhibitor

o Completed IND-enabling studies for OD-002, a first-in-class oral SLC15A4 inhibitor. OD-002 targets SLC15A4, a convergence point that integrates upstream TLR7, TLR8 and TLR9 signaling to activate IRF5. By targeting this convergence point, OD-002 is designed to broadly modulate disease-driving innate immune pathways, including TLR7/8/9-mediated responses implicated in pathogenic B-cell activity, autoantibody production, and pro-inflammatory cytokine signaling, while preserving normal host defense functions of IRF5.

• OD-003: TNFR2 agonist

o Upcoming presentation of preclinical data at ACR Convergence 2026. Odyssey will present preclinical data demonstrating expansion of regulatory T cells (Tregs) with enhanced stability, suppressive function and tissue-homing potential at the American College of Rheumatology (ACR) Convergence 2026 meeting, taking place November 6-11. The findings support the therapeutic potential of OD-003 across autoimmune and inflammatory diseases as the program advances through IND-enabling studies.

• OD-004: TSLP/IL-33 bispecific antagonist

o Nominated development candidate for OD-004. Odyssey selected a development candidate for OD-004, its potentially best-in-class TSLP/IL-33 bispecific antagonist, with potency for both targets comparable or superior to approved and investigational monospecific agents. The program is advancing into IND-enabling studies.

Corporate highlights

• Ensured continuity of clinical leadership with appointment of chief medical officer. Odyssey appointed Anthony Opipari, M.D., Ph.D., as chief medical officer.

Dr. Opipari joined Odyssey at its formation and played a central role in the design and execution of the Phase 2a OD-001 monotherapy trial in ulcerative colitis, overseeing its rapid advancement from initiation through completion while maintaining rigorous standards of clinical quality, data integrity, and operational execution. The trial established clinical proof of concept for OD-001 and demonstrated Odyssey's ability to execute efficiently in a competitive therapeutic area. His appointment ensures continuity of proven clinical leadership as Odyssey advances OD-001 into its next phase of development and progresses its broader pipeline.

• Strengthened organizational leadership and operational capabilities with appointment of chief people

2026
Q2

Q2 2026 Earnings

8-K

Aug 4, 2026

0001193125-26-331512

EX-99.1

2 odtx-ex99_1.htm

EX-99.1

EX-99.1

Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Data from the Phase 2a monotherapy trial of OD-001 accepted for oral presentation at United European Gastroenterology Week in October

Phase 2a combination trial of OD-001 with vedolizumab and Phase 2b monotherapy trial of OD-001 expected to initiate in 2H 2026

Cash on hand as of June 30, 2026 of $433.1M expected to fund operations into the second half of 2028

BOSTON, August 4, 2026 (GLOBE NEWSWIRE) — Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today reported financial results for the second quarter ended June 30, 2026 and provided an update on recent progress and anticipated milestones.

“Positive clinical proof-of-concept data for OD-001 marked an important milestone for Odyssey and we look forward to sharing additional, supportive data from this trial in October,” said Gary D. Glick, Ph.D., President and Chief Executive Officer of Odyssey. “We are focused on continuing to build momentum for this program as we prepare to initiate the next monotherapy trial and the first combination trial for OD-001 later this year. In addition, we plan to file a CTA for our second clinical program, OD-002, an oral SLC15A4 inhibitor designed to selectively modulate pathogenic B cell populations to treat autoimmune disease, by the end of this year.”

Second Quarter Business Highlights and Recent Developments

Pipeline Highlights

• OD-001: Small molecule RIPK2 scaffolding inhibitor

o Treatment with OD-001 in the Phase 2a expansion cohort is now complete, with data analyses ongoing. Updated safety and efficacy results from the full Phase 2a induction dataset, including expansion cohort, as well as assessments of exploratory endpoints, are expected to be presented in an oral presentation at the United European Gastroenterology (UEG) Week in October.

o Odyssey continues to expect the RIPK2 program to enter its next stage of clinical development, with initiation of a Phase 2b monotherapy trial and Phase 2a combination trial with vedolizumab expected in the second half of 2026. Additional details on both studies are expected to be shared in the second half of 2026.

Anticipated Key Clinical Milestones

• OD-001 (RIPK2 scaffolding inhibitor): Initiate a Phase 2b monotherapy trial and Phase 2a combination trial with vedolizumab in the second half of 2026, with topline induction data from both studies expected in the second half of 2027.

• OD-002 (SLC15A4 inhibitor): Complete investigational new drug (“IND”)-enabling studies and file a clinical trial application (“CTA”) in the second half of 2026, enabling initiation of a Phase 1/2a clinical trial in the first half of 2027 in healthy participants, followed by patient cohorts across a number of diseases, including cutaneous lupus erythematosus and additional autoimmune diseases.

Second Quarter 2026 Financial Results

As of June 30, 2026, Odyssey had cash, cash equivalents and marketable securities of $433.1 million, which are expected to fund Odyssey’s operations into the second half of 2028.

Research and development expenses were $36.2 million for the quarter ended June 30, 2026, compared to $30.2 million for the same period in 2025. The change primarily reflected an increase in external research and development costs associated with advancing the Company’s clinical and preclinical programs. General and administrative expenses were $10.5 million for the quarter ended June 30, 2026, compared to $13.2 million for the same period in 2025. The decrease primarily reflected lower legal and accounting professional fees than were recorded in the corresponding period for the prior year.

Net loss was $52.8 million for the quarter ended June 30, 2026, compared to a net loss of $41.2 million for the same period in 2025. Adjusted net loss (non-GAAP) was $38.4 million for the quarter ended June 30, 2026, after excluding $8.7 million of non-cash charges related to the change in the fair value of contingent consideration and $5.7 million of stock-based compensation expense. See “Non-GAAP Financial Measures” below for additional information and a reconciliation to the most directly comparable GAAP financial measure.

Additional financial information will be available in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, to be filed with the U.S. Securities and Exchange Commission and will be accessible at www.sec.gov and through the “Investors” section of the Company’s website at investors.odysseytx.com.

Non-GAAP Financial Measures

This press release includes adjusted net loss, a financial measure that is not prepared in accordance with U.S. generally accepted accounting principle

2026
Q1

Q1 2026 Earnings

8-K

Jun 17, 2026

0001193125-26-274291

EX-99.1

2 odtx-ex99_1.htm

EX-99.1

EX-99.1

Exhibit 99.1

Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Reported positive clinical proof-of-concept data for OD-001, our first-in-class, oral RIPK2 scaffolding inhibitor, in a Phase 2a monotherapy trial for moderate to severe ulcerative colitis

Cash on hand as of March 31, 2026, together with net proceeds from the IPO, and concurrent private placement, of $464M expected to fund operations into the second half of 2028

BOSTON, June 17, 2026 (GLOBE NEWSWIRE) — Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today reported financial results for the first quarter ended March 31, 2026 and highlighted progress across its clinical and preclinical portfolio.

“During the quarter, we continued to build meaningful momentum and made significant progress across our portfolio, including delivering clinical proof-of-concept for our oral, small molecule, RIPK2 scaffolding inhibitor, OD-001, in moderate-to-severe ulcerative colitis” said Gary D. Glick, Ph.D., President and Chief Executive Officer of Odyssey. “We look forward to rapidly advancing OD-001 into late-stage development and a series of combination trials with standard of care therapies to deliver on our aim of breaking the therapeutic ceiling in inflammatory bowel disease and providing a safe, oral medicine for long-term disease management. In addition, we expect to use the net financing proceeds to support advancement of our broader portfolio, including our small molecule SLC15A4 inhibitor, OD-002, for which we expect to file a CTA in the second half of 2026.”

First Quarter Business Highlights and Recent Developments

Pipeline Highlights

• OD-001: Small molecule RIPK2 scaffolding inhibitor

o Achieved clinical proof-of-concept in a Phase 2a clinical trial of OD-001 in moderate to severe ulcerative colitis. 49 patients completed 12 weeks of treatment with OD-001 and were eligible for efficacy analysis. OD-001 was well tolerated at both doses tested and observed to be efficacious in patients naïve, or experienced, to advanced therapies, with 27% of patients achieving clinical remission and 61% achieving clinical response.

o Odyssey is continuing to advance OD-001 and expects to initiate both a Phase 2b monotherapy trial and a Phase 2a combination trial with vedolizumab in the second half of 2026, with topline induction data from both trials expected in the second half of 2027.

Corporate Highlights

• Closed initial public offering and concurrent private placement, resulting in gross proceeds of $314.8M

o Closed an initial public offering of 15,500,000 shares of common stock and a concurrent private placement of 1,388,889 shares of common stock at the initial public offering price of $18.00 per share. Following the closing of the Company’s initial public offering, the underwriters partially

exercised their option to purchase 600,000 additional shares of common stock at $18.00 per share. All the shares of common stock sold in these transactions were offered by Odyssey with gross proceeds, before deducting underwriting discounts and commissions, placement agent fees, and other offering expenses, of $314.8M. Odyssey began trading on the Nasdaq Capital Market under the ticker symbol “ODTX” on May 8, 2026.

Anticipated Key Clinical Milestones

• OD-001 (RIPK2 scaffolding inhibitor): Initiate a Phase 2b monotherapy trial and a Phase 2a combination trial with vedolizumab in the second half of 2026, with results from both studies expected in the second half of 2027. Results from the signal-seeking Phase 2a monotherapy trial, for which topline induction data were released in April 2026, will be presented in the second half of 2026.

• OD-002 (SLC15A4 inhibitor): Complete investigational new drug (“IND”) enabling studies and file a clinical trial application (“CTA”) in the second half of 2026, which would enable the initiation of a Phase 1/2a clinical trial with healthy participants and patients in the first half of 2027.

First Quarter 2026 Financial Results

As of March 31, 2026, Odyssey had cash, cash equivalents and marketable securities of $175.7 million, which, together with the $288.7 million of net proceeds raised as part of its initial public offering, and concurrent private placement, are expected to fund Odyssey’s operations into the second half of 2028. Odyssey’s pro-forma cash position as of March 31, 2026, after giving effect to the net proceeds from these financing events, is $464.4M.

Research and development expenses were $32.3 million for the quarter ended March 31, 2026, compared to $38.8 million for the same period in 2025. The change primarily reflected a non-cash lease impairment charge recorded in the correspondin

Share on Social Networks: